Quantifying metal-induced susceptibility artifacts of the instrumented spine at 1.5T using fast-spin echo and 3D-multispectral MRI.

PURPOSE: To evaluate magnetic resonance imaging (MRI) artifacts near metallic spinal instrumentation using both conventional metal artifact reduction sequences (MARS) and 3D multispectral imaging sequences (3D-MSI). MATERIALS AND METHODS: Both MARS and 3D-MSI images were acquired in 10 subjects with titanium spinal hardware on a 1.5T GE 450W scanner. Clinical computed tomography (CT) images were used to measure the volume of the implant using seed-based region growing. Using 30-40 landmarks, the MARS and 3D-MSI images were coregistered to the CT images. Three independent users manually segmented the artifact volume from both MR sequences. For five L-spine subjects, one user independently segmented the nerve root in both MARS and 3D-MSI images. RESULTS: For all 10 subjects, the measured artifact volume for the 3D-MSI images closely matched that of the CT implant volume (absolute error: 4.3 ± 2.0 cm3 ). The MARS artifact volume was ∼8-fold higher than that of the 3D-MSI images (30.7 ± 20.2, P = 0.002). The average nerve root volume for the MARS images was 24 ± 7.3% lower than the 3D-MSI images (P = 0.06). CONCLUSION: Compared to 3D-MSI images, the higher-resolution MARS images may help study features farther away from the implant surface. However, the MARS images retained substantial artifacts in the slice-dimension that result in a larger artifact volume. These artifacts have the potential to obscure physiologically relevant features, and can be mitigated with 3D-MSI sequences. Hence, MR study protocols may benefit with the inclusion both MARS and 3D-MSI sequences to accurately study pathology near the spine. LEVEL OF EVIDENCE: 2 J. Magn. Reson. Imaging 2017;45:51-58.

External calibration of the spectral coverage for three-dimensional multispectral MRI.

PURPOSE: By combining images created at distinct frequency offsets from the Larmor frequency, three-dimensional (3D) multispectral imaging (3D-MSI) sequences help overcome the large spatial frequency dispersion caused by metal implants. This frequency dispersion, however, varies with the implant size, orientation, and composition. Using a MAVRIC 3D-MSI acquisition, we sought to prospectively calibrate the spectral coverage needed for 3D-MSI scans. This calibration should offer a significant improvement to image quality, and reduce the scan time. METHODS: The 24 spectral bins from the calibration scan were used to generate a map of frequency offsets around the implant. The magnitude image was used to remove any outliers in the associated frequency offset map, and this processed map was used to determine the cutoff frequency offset and, hence, number of spectral bins. This approach was tested in 13 subjects, by retrospectively reconstructing MAVRIC-SL images with fewer spectral bins. Subsequently, the spectral coverage for MAVRIC-SL images was prospectively calibrated in six subjects, and based on the cutoff frequency offset, these images were acquired with fewer spectral bins. RESULTS: With fewer spectral bins, both retrospectively and prospectively calibrated MAVRIC-SL images adequately delineated the implant boundary. CONCLUSION: Incorporating this calibration procedure into future 3D-MSI exams will help improve image signal-to-noise ratio, reduce scan time, and significantly improve clinical workflow when imaging near orthopedic implants. Magn Reson Med 76:1494-1503, 2016. © 2015 International Society for Magnetic Resonance in Medicine.

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.

PURPOSE: Dismal prognosis and limited treatment options for recurrent high-grade glioma have provoked interest in various forms of reirradiation. Pulsed reduced dose rate radiation therapy (pRDR) is a promising technique that exploits low-dose hyper-radiosensitivity of proliferating tumor cells while sparing adjacent nonproliferating normal brain tissue. Large radiation treatment volumes can thus be used to target both contrast-enhancing and FLAIR abnormalities thought to harbor recurrent gross and microscopic disease, respectively. The aim of this retrospective study was to determine whether the addition of pRDR to bevacizumab improves survival over bevacizumab alone for recurrent high-grade glioma. METHODS AND MATERIALS: Eighty patients with recurrent high-grade glioma were included in this study; 47 patients received bevacizumab monotherapy (BEV), and 33 patients received pRDR with bevacizumab (BEV/pRDR). Progression-free survival (PFS) and overall survival were compared between the BEV and BEV/pRDR groups. Regression analysis was performed to identify and control for confounding influences on survival analyses. RESULTS: Significant (P < .05) advantages in PFS (12 vs 4 months; hazard ratio = 2.37) and OS (16 vs. 9 months; hazard ratio = 1.68) were observed with BEV/pRDR compared with BEV alone. CONCLUSIONS: This retrospective analysis suggests that treatment with pRDR in addition to bevacizumab could significantly prolong PFS and overall survival compared with bevacizumab alone for recurrent high-grade glioma.